| Abstract: |
Twenty-five untreated patients with advanced, resectable squamous cell carcinoma of the hypopharynx, for whom standard treatment would have required total laryngectomy, were treated with one to three cycles of cisplatin-based chemotherapy with larynx preservation as the goal. Patients with a major (complete or partial) response to chemotherapy at the primary site were treated with definitive radiation therapy, with total laryngectomy reserved for salvage; patients with less than a partial response to chemotherapy had total laryngectomy and postoperative radiation therapy recommended. Four patients had a poor response to chemotherapy and thus were not candidates for laryngectomy. Total largynectomy was required for initial induction chemotherapy failure in five patients and for local recurrence in five others. Three additional patients had unresectable recurrence. Successful larynx preservation was achieved in 32% (8 of 25). With a median follow-up period of 41 months, the actuarial overall and failure-free 2-year survival rates were 44% and 32%, respectively. These preliminary data suggest larynx preservation is feasible in patients with advanced lesions of the hypopharynx. Improved local and regional control must be incorporated into the larynx preservation approach for hypopharyngeal lesions. A prospective, randomized study is necessary for a more valid comparison with conventional therapy, including comparative assessments of survival, morbidity, cost and functional results. © 1994, Official journal of the American Academy of Otolaryngology–Head and Neck Surgery Foundation. All rights reserved. |
| Keywords: |
adolescent; adult; cancer survival; clinical article; aged; survival analysis; retrospective studies; clinical trial; cancer recurrence; laryngectomy; squamous cell carcinoma; carcinoma, squamous cell; cisplatin; fluorouracil; cancer combination chemotherapy; multimodality cancer therapy; cancer radiotherapy; combined modality therapy; cancer staging; neoplasm recurrence, local; antineoplastic combined chemotherapy protocols; vinblastine; bleomycin; cobalt 60; hypopharynx cancer; hypopharyngeal neoplasms; middle age; human; male; female; article; support, non-u.s. gov't; support, u.s. gov't, p.h.s.
|
